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Abstract
Background: Gastrointestinal stromal tumors (GISTs) are characterized by mutations of KIT (v-kit Hardy-Zuckerman 4
feline sarcoma viral oncogene homolog) or PDGFRA (platelet-derived growth factor receptor α) that may be
efficiently targeted by tyrosine kinase inhibitors (TKI). Notwithstanding the early responsiveness to TKI, the majority
of GISTs progress, imposing the need for alternative therapeutic strategies. DOG1 (discovered on GIST-1) shows a
higher sensitivity as a diagnostic marker than KIT, however its prognostic role has been little investigated.
Methods: We evaluated DOG1 expression by immunohistochemistry (IHC) in 59 patients with GISTs, and correlated
its levels with clinical and pathological features as well as mutational status. Kaplan-Meier analysis was also applied
to assess correlations of the staining score with patient recurrence-free survival (RFS).
Results: DOG1 was expressed in 66 % of CD117+ GISTs and highly associated with tumor size and the rate of wild-
type tumors. Kaplan-Meier survival analysis showed that a strong DOG1 expression demonstrated by IHC correlated
with a worse 2-year RFS rate, suggesting its potential ability to predict GISTs with poor prognosis.
Conclusions: These findings suggest a prognostic role for DOG1, as well as its potential for inclusion in the criteria
for risk stratification.
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Background
Gastrointestinal stromal tumors (GISTs) develop within
the digestive tract and harbor functional mutations of
KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog) and PDGFRA (platelet-derived
growth factor receptor-α) that primarily drive the tumor
growth and progression [1, 2]. KIT and PDGFRA genes
are located on the chromosome 4q12 and encode trans-
membrane glycoproteins belonging to the type III recep-
tor tyrosine kinase family. They are normally activated
by their ligands, namely stem cell factor and PDGF re-
spectively, which bind the receptor extracellular domain
leading to the dimerization of receptors and phos-
phorylation of tyrosines in their cytoplasmic tyrosine
kinase (TK) domains in a process called signal trans-
duction. This triggers a phosphorylation cascade of
the tyrosine residues in multiple downstream molecules
and leads to the activation of signal transduction pathways
involved in many important cell functions such as prolifer-
ation, apoptosis, chemotaxis and adhesion [3]. The pres-
ence of KIT and PDGFRA activating mutations provides
the rationale for employing targeted therapies using spe-
cific inhibitors (TKI), that can improve recurrence-free
survival (RFS) and overall survival (OS) in the majority of
patients. The currently used systems for risk stratification
are based on tumor size and site, mitotic count and tumor
rupture, whereas the prognostic relevance of mutational
status is still under debate [4]. CD117 expression occurs
in more than 95 % of GISTs bearing KIT or PDGFRA mu-
tations [5], the remaining 5 % are either CD117 negative
or wild-type (WT) for both genes. Thus, to obtain a defin-
ite diagnosis additional morphological and/or molecular
* Correspondence: frarizzo3@libero.it
1Department of Biomedical Sciences and Human Oncology, University of Bari
“A. Moro”, Piazza Giulio Cesare, 11-70124 Bari, Italy
Full list of author information is available at the end of the article
© 2016 Rizzo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rizzo et al. BMC Cancer  (2016) 16:87 
DOI 10.1186/s12885-016-2111-x
characterization may be required, such as searching for
germline or de novo mutations of SDH (succinate de-
hydrogenase) subunits located on the inner membrane of
the mitochondria, or even mutations of the RAS-pathway
[6]. Among the latter, the frequency of BRAF mutations
varies from 2 to 13 %, whereas KRAS mutations are ex-
tremely rare (<0.2 %). Interestingly, concomitant KRAS
mutations in KIT- or PDGFRA-mutated GISTs were re-
ported and, based on in vitro experiments, it has been de-
fined that the presence of RAS mutations predicts
resistance of KIT-mutated GISTs to TKI [7]. However,
two subsequent analysis in large cohort of GIST patients
have not found mutations in KRAS codons 12 and 13 or
61 [8, 9]. More recently, one single KIT/PDGFRA WT
GIST was identified to carry a KRAS mutation in codon
12 among 267 patients and associated with an aggressive
behavior and resistance to multiple TKI inhibitors [10].
DOG1 (Discovered on GIST-1) is a calcium-dependent
chloride channel protein regulating the cholinergic activ-
ity of gastrointestinal smooth muscle [11] that is
encoded by ANO1/TMEM16A on chromosome 11q13;
in these tumors its expression shows high sensitivity and
specificity [12, 13]. Other functions exerted by ANO1 in-
clude the regulation of both the viability and prolifera-
tion of cells overcoming their checkpoints within the
cell-cycle [14]. In addition, in DOG1+ cells ANO1 acti-
vates alternative signals downstream of the RAS/RAF/
MEK/ERK and the insulin-like growth factor (IGF)-
dependent pathways [15, 16]. These findings support the
hypothesis that DOG1 exerts a definite role in GIST de-
velopment, regardless of KIT and PDGFRA activation,
whereas its prognostic role is still debated.
Particularly in GISTs lacking CD117 expression and
bearing PDGFRA mutations [17, 18], DOG1 appears to
be a promising tool for diagnosis also of rare variants in-
cluding gastric spindle and epithelioid-cell PDGFRA-
mutated GISTs [19]. However, its expression has been
little correlated with other risk factors [20–22].
Here we explored the prognostic role of DOG1 in a
cohort of patients with GISTs, and evaluated the poten-
tial correlation between variable grades of expression
and known risk factors for recurrence.
Methods
Patients and specimens
Demographic data, histological and immunohistochemi-
cal features, as well as mutational status, of 59 patients
with GISTs, enrolled at the Medical Oncology Unit of
the University of Bari and the IRCCS San Raffaele Pisana
in Rome from 2007 to 2014, were collected after obtain-
ing patients’ written informed consent and approval by
the Ethics Committee of the University of Bari and the
Ethics Committee of IRCCS San Raffaele Pisana in
Rome, in accordance with the principles embodied in
the Declaration of Helsinki. Selected hematoxylin/eosin
stained slides were reviewed to confirm the diagnosis, as
well as tumor features including size and histology;
CD117 expression was evaluated by immunohistochem-
istry (IHC). In each sample the number of mitoses was
evaluated in 50 consecutive high-power fields (HPFs),
while demographic data including tumor staging at diag-
nosis and follow-up were retrieved from medical records.
Mutational analysis of PDGFRA or KIT genes
Tumor specimens were screened for hot-spot mutation
sites of PDGFRA (exons 12 and 18) and KIT (exons 9,
11, 13 and 17) genes. To this end, genomic DNA was
isolated from formalin-fixed, paraffin-embedded (FFPE)
tissues containing at least 70 % of neoplastic cells.
Tumor sections of 8–10 μm were incubated in xylene
and then washed with absolute ethanol. DNA was iso-
lated from the air-dried tissues using the QIAamp® DNA
FFPE Tissue Kit (QIAGEN, Hilden, Germany) according
to the manufacturer’s instructions. Screening of muta-
tions was performed by direct sequencing of the PCR
products obtained using primer pairs designed to select-
ively amplify PDGFRA exons 12 and 18 and KIT exons
9, 11, 13 and 17. PCR reactions were performed using
100 ng of DNA with the primers listed in Additional
file 1: Table S1. Mutation analysis was assessed by se-
quencing of PCR products with the same primers
used for PCR reactions and the BigDye® Terminator
v1.1 cycle sequencing kit (Applied Biosystems). Sam-
ple analysis was performed on an ABI PRISM 310
Genetic Analyzer (Applied Biosystems).
Immunohistochemistry
The expression of DOG1 was investigated by IHC with
the anti-DOG1 monoclonal antibody (MoAb; clone K9,
Abcam Cambridge, MA). Five μm FFPE sections of each
primary tumor were treated according to the staining
Dako Autostainer protocol (Burlington, Ontario,
Canada). Briefly, sections were incubated with the anti-
DOG1 MoAb at 1:100 dilution for 30 min at room
temperature. Stained specimens were analyzed by two
pathologists and results were scored according to the
Allred scoring system, including a semi-quantitative
method to reveal the staining intensity (0 = negative;
1 = weak/trace; 2 = moderate; 3 = strong) and the per-
centage of positive cells (0 = normal cells; 1 = ≤ 1 %;
2 = 1–10 %; 3 = 11–33 %; 4 = 34–66 %; 5 = 67–100 %).
This grading produced a final score [23] that was re-
ported as negative (score 0), weak (score 1–3), mod-
erate (score 4–6) or strong (score 7–8).
Statistical analysis
Fisher’s exact test was used to evaluate differences be-
tween independent groups. The p-values for differences
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between subgroups were adjusted by a permutational
test performed in the multitest SAS STAT procedure.
Comparison between independent groups was per-
formed by t-test, given the Gaussian distribution of data.
Statistical analysis was performed using SAS 9.4 soft-
ware. Recurrence-free survival (RFS) was defined as the
time from the date of operation to the date of recur-
rence and/or distant metastasis. Patients who survived
without recurrence and/or metastasis were censored on
the date of the last follow-up. RFS was calculated accord-
ing to the Kaplan-Meier method and the survival distribu-
tions were compared by log-rank test. A p-value <0.05
was considered statistically significant.
Results
Demographics
As shown in Table 1, 59 patients with GISTs were en-
rolled in the study (57 locally-advanced and 2 metastatic;
31 males (52.5 %) and 28 females (47.5 %), median age
63.3 ± 14.6 years). Primary sites included the stomach
(n = 39; 66.1 %), small (n = 12; 20.3 %) and large
bowel (n = 4; 6.8 %), as well as extra-gastrointestinal
sites (n = 4; 6.8 %) including the pancreas and retro-
peritoneum. The histological subtypes included spindle-
cell (n = 45; 76.3 %), epithelial (n = 6; 10.2 %) and mixed
(n = 8; 13.5 %) variants. Mean tumor size was 8.3 ± 5.5 cm,
while the number of mitoses (HPFx50) was ≤5 in 25
(42.4 %), 6–10 in 17 (28.8 %) and ≥10 in 17 (28.8 %)
patients. Despite slight variations in CD117 staining
intensity, it was considered positive in all patients.
Mutational status was available in 53 patients harbor-
ing mutations of KIT (n = 35; 66.1 %) and PDGFRA
(n = 4; 7.5 %) (Fig. 1), whereas in 14 patients (26.4 %)
both genes were WT. The identified hot-spot muta-
tions are listed in Additional file 2: Table S2. The
average follow-up was 36 + 21 months; 22 % of pa-
tients (n = 13) had evidence of disease recurrence.
DOG1 expression in GISTs correlates with clinical and
pathological features
Based on the IHC DOG1 expression, 39 patients
(66.1 %) were included in Group A (DOG1+) and 20
(33.9 %) in B (DOG1−). Representative panels from both
groups are included in Fig. 2, showing strong (a), moder-
ate (b) and weak (c) as well as negative (d) cytoplasmic
or membranous DOG1 expression. Based on the Allred
scoring system, a strong DOG1 expression was demon-
strated in 24 Group A patients (Group A1), moderate
levels in 12 (Group A2) and a weak expression in 3 pa-
tients (Group A3). Levels of DOG1 expression did not
correlate with gender, age, primary site, histology, mi-
toses or mutational status (Table 1). By contrast, tumor
size in Group A patients was greater (10.1 ± 5.8 cm)
than in Group B (4.7 ± 1.9 cm; p = 0.0002), whereas
the frequency of the WT status for both KIT and
PDGFRA was lower in Group A than B (14.3 % vs.
50 %; p = 0.009).
DOG1 expression levels and GIST outcome
DOG1 expression was investigated in relation to a po-
tential predictive role with respect to the onset of recur-
rence. Nine Group A patients (23 %) and four Group B
Table 1 Clinical pathological features of the 59 GIST cases








Male, n (%) 31 (52.5 %) 19 (48.7 %) 12 (60 %) p = 0.413
Female, n (%) 28 (47.5 %) 20 (51.3 %) 8 (40 %)
Age (years)
Mean (±SD) 63.3 (±14.6) 63.1 (±16.9) 63.6 (±12.8) p = 0.8973
Median 67 65 66.5
Range 28–88 28–88 34–82
Primary site p = 0.0652
Stomach 39 (66.1 %) 29 (74.3 %) 10 (50 %)
Small intestine 12 (20.3 %) 8 (20.5 %) 4 (20 %)
Large bowel 4 (6.8 %) 1 (2.6 %) 3 (15 %)
Others 4 (6.8 %) 1 (2.6 %) 3 (15 %)
Tumor size (cm) p = 0.0002
Mean (±SD) 8.3 (±5.5) 10.1 (±5.8) 4.7 (±1.9)
Median 6 8 4.7
Range 2–20 3–20 2–10
Histological subtype p = 0.2
Spindle type 45 (76.3 %) 27 (69.2 %) 18 (90 %)
Epithelial type 6 (10.2 %) 5 (12.8 %) 1 (5 %)
Mixed type 8 (13.5 %) 7 (18 %) 1 (5 %)
Mitoses per 50 HPFs
≤ 5 25 (42.4 %) 15 (38.5 %) 10 (50 %) p = 0.54
6–10 17 (28.8 %) 13 (33.3 %) 4 (20 %)
≥ 10 17 (28.8 %) 11 (28.2 %) 6 (30 %)
Mutated exon
KIT exon 11 30 (56.6 %) 24 (68.6 %) 6 (33.5 %) p = 1
KIT exon 9 2 (3.8 %) 2 (5.7 %) 0
KIT exon 13 2 (3.8 %) 2 (5.7 %) 0
KIT exon 17 1 (1.9 %) 0 1 (5.5 %)
PDGFRA exon 12 1 (1.9 %) 0 1 (5.5 %) p = 0.889
PDGFRA exon 18 3 (5.6 %) 2 (5.7 %) 1 (5.5 %)
Wild type 14 (26.4 %) 5 (14.3 %) 9 (50 %) p = 0.009
Not available 6 4 2
HPF high power field of the microscope; p-values computed using Fisher exact
test or χ2 test
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(20 %) recurred during follow-up, yielding 2-year RFS
rates of 84 and 95 % respectively. The cumulative RFS
curve in Group A patients was worse, although not sig-
nificantly so, compared to Group B (Fig. 3a). We also in-
vestigated the relationship between DOG1 levels and
RFS, and found that Group A1 patients had the worst
2-year (panel b) RFS rate (80 %; 6/24) as compared
to the other groups (93 %; 7/35). Further analyses
were performed to investigate whether the previously
described correlation of DOG1 expression with both
tumor size and mutational status was associated with
the RFS. Therefore, Group A1 patients were subdivided






Fig. 1 Sequencing analysis. Direct sequencing analysis of the PCR products showing a substitutions of GTT (Val) to GAT (Asp) at codon 559 of KIT
gene (panel a) and GAC (Asp) to GTC (Val) at codon 842 of PDGFAR gene (panel b)
a b
c d
Fig. 2 DOG1 measurement according to the Allred scoring system. Representative panels showing the variable DOG1 expression by IHC in
patients with GISTs: strong (score: 7–8, panel a), moderate (score: 4–6, b) and weak (score: 1–3, c), while panel d shows a DOG1 negative
specimen. Magnification is 200x in a, b and c, 100x in d
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by tumor size greater (n = 14) or smaller (n = 10) than
5 cm. As shown in panel c, the Kaplan-Meier survival
curve revealed 2-year RFS rates of 66 % (6/14 events) and
100 % respectively (p = 0.01). Moreover, among A1 pa-
tients with a tumor size >5 cm (panel d), those carrying a
KIT or PDGFRA mutation (n = 11) had a worse prognosis
than the WT (n = 3), the 2-year RFS rates being 58 and
100 % respectively. The trend to statistical significance
(p = 0.16) was, however, influenced by the sample size.
Discussion
GISTs are rare tumors with morphological, histological
and molecular features that strongly influence both the
outcome and risk of recurrence. Since the discovery of
the role of oncogenic mutations of KIT and PDGFRA,
targeted therapy with TKI has significantly increased the
OS in the majority of patients. However, WT GISTs or
those harboring rare mutations often experience pro-
gression or recurrence and so a better risk stratifica-
tion is needed in order to plan adequate therapeutic
strategies.
Measurement of DOG1 expression by IHC has been
associated with a higher diagnostic sensitivity and speci-
ficity than CD117, allowing the diagnosis of GISTs in
about 30 % of CD117-negative patients [18]. Its expres-
sion has been described in both normal and malignant
tissues, although its prognostic role is still being debated.
The DOG1 protein mediates the receptor-activated
chloride current whose levels modulate the cell prolif-





Fig. 3 Kaplan-Meier cumulative RFS. a The 2-year RFS rate of DOG1-positive patients (Group A) was 84 % (dashed line; p = 0.2) as compared to
DOG1-negative patients (95 %; solid line; Group B). Disease recurrence occurred in 9/39 and 4/20 patients, respectively. b Group A patients were
divided by the Allred scoring system into 3 sub-groups (A1, A2 and A3) based on the DOG1 expression levels, indicated as strong, moderate
and weak, respectively. The 2-year RFS rate for A1 patients was 80 % (dashed line) compared to 93 % for A2 + A3 + B patients (solid line; p = 0.2).
Disease recurrence occurred in 6/24 and 7/35 patients, respectively. c Group A1 patients were divided by tumor size greater or smaller than 5 cm.
The 2-year RFS rate for patients bearing tumors >5 cm was 66 % (dashed line) with 6/14 events compared to 100 % for those with tumors >5 cm
(ten patients) (solid line; p = 0.01). d The 14 Group A1 patients with tumor size > 5 cm were subdivided by mutational status, and the 2-year RFS
rate for those (n = 11) harboring mutations was 58 % (solid line) compared to 100 % for the 3 WT patients (dashed line, p = 0.16). Recurrence
occurred in 6/11 Group A1 patients
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suppressor protein phosphorylation [14, 24, 25], or by
activating the MEK/ERK pathway [15]. In addition,
xenograft DOG1−/− models of GISTs show an im-
paired cell proliferation as a consequence of the de-
creased IGF binding protein-5 levels [16], that inhibit
IGF-mediated downstream signals by trapping both
IGF1 and IGF2 [26]. These findings suggest that
DOG1 over-expression provides a proliferative advan-
tage to malignant stromal cells, and increased levels
could negatively influence prognosis.
Here, we describe results from an observational study
based on evaluation of the clinical, pathological and mo-
lecular features of 59 GIST patients and any correlations
with DOG1 expression. Approximately 66 % of CD117+
samples showed a strong DOG1 expression, in agree-
ment with previous studies describing its variable accu-
mulation in 60–99 % malignant cells. The reported
variability in DOG1 expression was mostly attributed to
different monoclonal antibodies used for IHC analyses,
as well as to the intrinsic characteristics of the speci-
mens [10, 21, 27]. In accordance with previous studies
[19–21, 28], our data showed that DOG1 expression is
unrelated to gender, age, primary site, histological sub-
types and mitoses, although a significant correlation was
demonstrated with large tumors harboring an unfavor-
able mutational status. Tumor size is already considered
a prognostic factor for the definition of high-risk disease
[29–31]. However, the prognostic role of the mutational
status is still under debate and not included in the
current risk stratification systems. It is noteworthy that
the presence of the homozygous KIT exon-11 mutation
predicts an aggressive disease course, in particular when
deletions affect both codons 557–558 [32]. By contrast,
the majority of PDGFRA mutated GISTs show a benign
course [33]. Our data support those recently published
in a meta-analysis on 1487 patients [34], proving that
GISTs bearing KIT mutations have a significantly poorer
prognosis than either PDGFRA mutated or WT GISTs.
Moreover, Rìos-Moreno et al. reported that the WT
genotype was prevalent in DOG1−/CD117− patients [35].
We demonstrated a more favorable post-operative 2-year
RFS rate in DOG1-negative patients than DOG1-positive
patients (p = 0.02). These findings were in line with previ-
ous results [36] that reported a significant association
between DOG1 expression and high-risk tumors. We
stratified DOG1 positive patients in relation to the Allred
scoring system to identify those with a higher risk of re-
currence; in our study patients with a strong DOG1 ex-
pression, tumor size ≥ 5 cm and mutations of KIT or
PDGFRA had a worse prognosis.
The genetic landscape of GIST patients should be fur-
ther investigated. In particular, given the correlation
between DOG1 expression and the activation of the
downstream RAS/RAF/MEK/ERK signaling pathway, the
clinical significance of activating RAS mutations remains
to be better elucidated for its therapeutic relevance, as
already widely investigated in other tumors [37].
Conclusions
In conclusion, in our patients a high DOG1 expression
correlated with an aggressive malignant phenotype of
GISTs. Thus, measurement of DOG1 expression would
be helpful in clinical practice to predict the recurrence
risk in GIST patients. We believe that the Allred scoring
system could be integrated in current risk stratification
systems to achieve a better identification of patients at
increased risk of recurrence.
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